



(12) Translation of
European patent specification

(11) NO/EP 3954225 B1

NORWAY

(19) NO
(51) Int Cl.
A23L 33/13 (2016.01)
A61K 31/711 (2006.01)
A61K 31/7115 (2006.01)
A61K 31/712 (2006.01)
C07H 21/02 (2006.01)
C12N 15/11 (2006.01)
C12P 19/34 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.03.11
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.11.22
(86)	European Application Nr.	21173142.7
(86)	European Filing Date	2016.09.20
(87)	The European Application's Publication Date	2022.02.16
(30)	Priority	2015.09.21, US, 201562221248 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP3352584, 2016.09.20
(73)	Proprietor	TriLink BioTechnologies, LLC, 10770 Wateridge Circle, Suite 200, San Diego, CA 92121, USA
(72)	Inventor	HOGREFE, Richard I., San Diego, CA 92109, USA LEBEDEV, Alexandre, San Diego, CA 92121, USA MCCAFFREY, Anton P., San Diego, CA 92109, USA SHIN, Dongwon, San Diego, CA 92131, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge


(54)	Title	INITIATING CAPPED OLIGONUCLEOTIDE PRIMERS FOR SYNTHESIZING 5'-CAPPED RNAS
(56)	References Cited:	WO-A2-2009/058911 WO-A2-2008/016473 I. I. KOUKHAREVA ET AL: "Chemical Route to the Capped RNAs", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS., vol. 23, no. 10, 1 January 2004 (2004-01-01), pages 1667-1680, XP055553747, US ISSN: 1525-7770, DOI: 10.1081/NCN-200031492 ROBERT E. SMITH ET AL: "A Unique Class of Compound, Guanosine-Nucleoside Tetraphosphate G(5')pppp(5')N, Synthesized during the in Vitro Transcription of Cytoplasmic Polyhedrosis Virus of Bombyx mori STRUCTURAL DETERMINATION AND MECHANISM OF FORMATION*", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 257, no. 1, 1 January 1982 (1982-01-01), pages 485-494, XP055331398,

M. Ishikawa ET AL: "Preparation of eukaryotic mRNA having differently methylated adenosine at the 5'-terminus and the effect of the methyl group in translation", Nucleic Acids Symposium Series, vol. 53, no. 1, 1 September 2009 (2009-09-01), pages 129-130, XP055331388, GB ISSN: 0261-3166, DOI: 10.1093/nass/nrp065

Y. THILLIER ET AL: "Synthesis of 5' cap-0 and cap-1 RNAs using solid-phase chemistry coupled with enzymatic methylation by human (guanine-N7)-methyl transferase", RNA, vol. 18, no. 4, 14 February 2012 (2012-02-14), pages 856-868, XP055553150, US ISSN: 1355-8382, DOI: 10.1261/rna.030932.111

HIROAKI SAWAI ET AL: "Synthesis and Reactions of Nucleoside 5'-Diphosphate Imidazolide. A Nonenzymatic Capping Agent for 5'-Monophosphorylated Oligoribonucleotides in Aqueous Solution", JOURNAL OF ORGANIC CHEMISTRY, vol. 64, no. 16, 1 August 1999 (1999-08-01), pages 5836-5840, XP055331109, ISSN: 0022-3263, DOI: 10.1021/jo990286u

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav**1. Forbindelse med den følgende struktur:**


hvor:

- 5 B_1 og B_{10} uafhængig af hverandre er en naturlig nukleosidbase;
 R_1 er H eller metyl;
 R_2 er H, OH, alkyl, O-alkyl eller halogen;
 R_3 er O-alkyl; og
 R_4 er H, OH eller O-metyl.

10

2. Forbindelse ifølge krav 1, hvor R_3 er O-metyl.**3. Forbindelse ifølge krav 1, hvor B_1 er adenin, guanin, N^6 -metyladenin, cytosin eller uracil.**

15

4. Forbindelse ifølge krav 1, hvor B_{10} er adenin, guanin, N^6 -metyladenin, cytosin eller uracil.**5. Forbindelse ifølge krav 1, som har strukturen:**

20

6. Forbindelse ifølge et hvilket som helst av kravene 1 til 5, hvor forbindelsen er en initierende capped oligonukleotidprimer.

7. Initierende capped oligonukleotidprimer ifølge krav 6, valgt

- 5 blant $m^7G_3'OmepppApA$, $m^7G_3'OmepppApC$, $m^7G_3'OmepppApG$, $m^7G_3'OmepppApU$,
 $m^7G_3'OmepppCpA$, $m^7G_3'OmepppCpC$, $m^7G_3'OmepppCpG$, $m^7G_3'OmepppCpU$,
 $m^7G_3'OmepppUpA$, $m^7G_3'OmepppUpC$, $m^7G_3'OmepppUpG$, $m^7G_3'OmepppUpU$,
 $m^7G_3'OmepppA_2'OmepA$, $m^7G_3'OmepppA_2'OmepC$, $m^7G_3'OmepppA_2'OmepG$,
 $m^7G_3'OmepppA_2'OmepU$, $m^7G_3'OmepppC_2'OmepA$, $m^7G_3'OmepppC_2'OmepC$,
10 $m^7G_3'OmepppC_2'OmepG$, $m^7G_3'OmepppC_2'OmepU$, $m^7G_3'OmepppU_2'OmepA$,
 $m^7G_3'OmepppU_2'OmepC$, $m^7G_3'OmepppU_2'OmepG$ og $m^7G_3'OmepppU_2'OmepU$.

8. RNA-molekyl som omfatter den initierende capped oligonukleotidprimer ifølge krav 6 eller krav 7.

15

9. Celle som inneholder et RNA-molekyl som omfatter den initierende capped oligonukleotidprimer ifølge krav 6 eller krav 7.

- 10.** Fremgangsmåte for fremstilling av en celle som inneholder et protein som er
20 translatert fra et RNA-molekyl, omfattende den initierende capped
oligonukleotidprimer ifølge krav 6 eller krav 7, omfattende innføring av nevnte
RNA-molekyl som inneholder den initierende capped oligonukleotidprimer, i en
celle som benytter nevnte RNA-molekyl for å produsere nevnte protein.

- 25 **11.** Farmasøytisk sammensetning som omfatter RNA-molekylet ifølge krav 8 og en
farmasøytisk akseptert bærer.